Ferring Pharmaceuticals Release: Similiar Remission Results Shown Between Once-Daily 4g Dose and Twice-Daily 2g Doses of Mesalazine (Pentasa®) in Active Ulcerative Colitis

STOCKHOLM--(BUSINESS WIRE)--Results of a new study1 presented today at the United European Gastroenterology Week (UEGW) congress in Stockholm demonstrate that a single daily 4g dose of mesalazine (Pentasa granules) is non-inferior to the standard, twice-daily 2g dose in inducing remission in patients with active ulcerative colitis.